NUR210 Exam 2: Principles of Pharmacology | Galen College of Nursing | 2026/2027 A+ Guarantee
NUR210 / NUR 210 Exam 2 (Latest 2026/2027)
Principles of Pharmacology - Galen Tested Questions with Revised Correct Answers
Section 1: Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion) -
Q1-Q10
Q1: A nurse is administering a medication orally to a client. The client asks why the oral dose is higher than the
intravenous dose of the same drug. Which response by the nurse is most accurate regarding the first-pass effect?
A. The oral form is less concentrated because the tablet contains fillers and binders that dilute the active
ingredient
B. The oral drug passes through the liver before reaching systemic circulation, where a significant portion is
metabolized and inactivated, reducing bioavailability
C. The intravenous form bypasses the kidneys, so more drug reaches the systemic circulation compared to the
oral route
D. Oral medications are absorbed more slowly through the stomach lining, requiring a higher dose to
compensate for delayed onset of action
Correct Answer: B
Rationale: The first-pass effect refers to the metabolism of a drug by the liver before it reaches the systemic circulation, which
significantly reduces the bioavailability of orally administered medications. Because a portion of the drug is metabolized and
inactivated during this initial hepatic passage, a higher oral dose is required to achieve the same therapeutic effect as a lower IV
dose that achieves 100% bioavailability. Option A incorrectly describes excipients, which do not affect bioavailability in this
manner. Option C is wrong because the first-pass effect involves the liver, not the kidneys. Option D confuses absorption rate
with bioavailability, which are distinct pharmacokinetic concepts aligned with Galen NUR210 competencies.
Q2: A client with liver cirrhosis is prescribed a medication that is highly protein-bound (98%). The nurse
understands that which factor most significantly affects the pharmacological activity of this drug in this client?
A. The drug will be rapidly excreted by the kidneys due to reduced protein binding sites in the blood
B. Only the unbound (free) fraction of the drug is pharmacologically active, and liver disease may alter
albumin levels, increasing the free drug concentration and risk of toxicity
C. The drug will accumulate in the liver tissue due to cirrhosis, leading to prolonged therapeutic effects
D. Protein-bound drugs are metabolized more quickly in clients with liver disease, reducing the drug half-life
Correct Answer: B
Rationale: Drugs bound to plasma proteins (primarily albumin) are pharmacologically inactive because they cannot cross cell
membranes or interact with receptors. Only the unbound (free) fraction is active. In liver cirrhosis, albumin production is
reduced, leaving fewer binding sites and increasing the free (active) drug concentration, which elevates the risk of toxicity even at
normal doses. This is a critical pharmacokinetic principle taught in Galen NUR210. Option A is incorrect because protein binding
affects distribution, not renal excretion directly. Option C describes distribution to tissues, not the mechanism of altered
pharmacological activity. Option D is false because protein binding does not accelerate metabolism; in fact, less protein binding
means more free drug available for metabolism.
Page 1
,NUR210 Exam 2: Principles of Pharmacology | Galen College of Nursing | 2026/2027 A+ Guarantee
Q3: A nurse is caring for a client receiving warfarin therapy. The healthcare provider prescribes phenytoin for a
new-onset seizure disorder. The nurse anticipates which therapeutic change based on the pharmacokinetic principle
of enzyme induction?
A. Warfarin levels will increase, raising the risk of bleeding, and the INR should be monitored more frequently
B. Phenytoin will increase the metabolism of warfarin by inducing hepatic CYP450 enzymes, decreasing
warfarin levels and potentially reducing its anticoagulant effect
C. Warfarin will inhibit the metabolism of phenytoin, leading to phenytoin toxicity and requiring a dosage
reduction
D. The combination will have an additive effect on the central nervous system, causing excessive sedation and
drowsiness
Correct Answer: B
Rationale: Phenytoin is a potent CYP450 enzyme inducer that increases the hepatic metabolism of warfarin, a drug with a
narrow therapeutic index that is metabolized by the same enzyme system. This enzyme induction accelerates warfarin
breakdown, reducing its plasma concentration and anticoagulant effect, potentially leading to thrombosis if the INR drops below
the therapeutic range of 2-3. The nurse should anticipate more frequent INR monitoring and a potential need to increase the
warfarin dose. Option A describes enzyme inhibition (the opposite effect). Option C reverses the interaction direction. Option D
describes a pharmacodynamic CNS effect that does not apply to these specific medications, reflecting a common NUR210
distractor pattern.
Q4: A client is prescribed a medication with a half-life of 12 hours. The nurse understands that approximately how
long it will take for this drug to reach steady-state therapeutic levels?
A. 12 hours, which equals one complete half-life cycle
B. 24 hours, or approximately two half-lives, which provides sufficient drug accumulation
C. 48 to 60 hours, or approximately 4 to 5 half-lives, at which point drug administration equals drug
elimination
D. 72 hours, or six half-lives, because this ensures maximum drug plasma concentration is achieved
Correct Answer: C
Rationale: Steady state is achieved when the rate of drug administration equals the rate of drug elimination, creating a plateau in
plasma concentration. It takes approximately 4 to 5 half-lives to reach steady state for most medications. For a drug with a
12-hour half-life, this would be 48 to 60 hours. This is a fundamental pharmacokinetic principle emphasized in the Galen
NUR210 curriculum. Option A (1 half-life) reaches only 50% of steady state. Option B (2 half-lives) reaches only 75% of steady
state. Option D (6 half-lives) exceeds the standard 4-5 half-life calculation and is unnecessary for clinical purposes.
Q5: A nurse is reviewing medication orders for a client with chronic kidney disease (CKD) stage 4. Which
pharmacokinetic alteration should the nurse expect for medications that are primarily eliminated by renal excretion?
A. Increased first-pass metabolism leading to reduced drug bioavailability
B. Decreased drug absorption from the gastrointestinal tract due to uremic toxins
C. Reduced renal clearance leading to drug accumulation, prolonged half-life, and increased risk of toxicity
D. Enhanced protein binding increasing the fraction of inactive drug in circulation
Correct Answer: C
Rationale: The kidney is the primary route of drug excretion through glomerular filtration, tubular secretion, and passive
reabsorption. In CKD stage 4, renal function is severely impaired (GFR 15-29 mL/min), leading to significantly reduced drug
Page 2
, NUR210 Exam 2: Principles of Pharmacology | Galen College of Nursing | 2026/2027 A+ Guarantee
clearance for renally eliminated medications. This causes drug accumulation, prolonged half-life, and increased risk of toxicity
unless dosage adjustments are made. This principle is central to safe medication administration in NUR210. Option A describes a
hepatic issue, not renal. Option B refers to absorption, which is not the primary pharmacokinetic concern in CKD. Option D is
incorrect because CKD does not enhance protein binding; it may actually reduce it due to hypoalbuminemia from uremia.
Q6: A postpartum client is breastfeeding and asks the nurse about medication excretion into breast milk. Which
pharmacokinetic factor best explains why some drugs cross into breast milk more readily than others?
A. Drugs with high molecular weight and extensive protein binding are more likely to enter breast milk
B. Drugs that are lipid-soluble, unbound (free), and have low molecular weight more readily cross into breast
milk by passive diffusion
C. Only water-soluble drugs can cross into breast milk because milk is primarily an aqueous environment
D. Drugs that are ionized at physiological pH are preferentially transported into breast milk via active transport
mechanisms
Correct Answer: B
Rationale: Breast milk excretion follows the same principles as distribution across biological membranes. Lipophilic
(lipid-soluble) drugs, unbound (free) drugs, and those with low molecular weight cross more readily into breast milk by passive
diffusion. The pH of breast milk is slightly acidic (pH ~7.0) compared to plasma (pH 7.4), so weakly basic drugs may become
ionized and trapped in milk (ion trapping). Option A is incorrect because high molecular weight and protein binding impede, not
facilitate, passage into breast milk. Option C is wrong because lipophilic, not water-soluble, drugs cross membranes more easily.
Option D is incorrect because ionized drugs do not cross membranes readily via passive diffusion, and only a few drugs use
active transport into milk.
Q7: A nurse is preparing to administer digoxin to a client with heart failure. The nurse understands that digoxin has a
narrow therapeutic index. Which statement best describes the clinical significance of a narrow therapeutic index?
A. The drug has a wide margin of safety, and small dosage variations rarely produce toxic effects
B. The therapeutic index (ratio of toxic dose LD50 to effective dose ED50) is small, meaning the difference
between a therapeutic dose and a toxic dose is minimal, requiring close monitoring
C. The drug requires a loading dose to achieve steady state because it has a very long half-life exceeding 48
hours
D. The drug is primarily metabolized by CYP3A4 and is highly susceptible to drug-drug interactions with
enzyme inhibitors
Correct Answer: B
Rationale: The therapeutic index (TI) is the ratio of the toxic dose (LD50) to the effective dose (ED50). A narrow therapeutic
index means this ratio is small, indicating that the difference between a therapeutic and toxic dose is minimal. Digoxin, along
with warfarin, lithium, theophylline, and phenytoin, are classic examples of narrow therapeutic index drugs that require close
serum level monitoring, precise dosing, and vigilant assessment for signs of toxicity. Option A describes a wide therapeutic
index, which is the opposite. Option C describes a pharmacokinetic property (half-life) related to loading dose rationale, not
therapeutic index. Option D describes a drug interaction risk related to metabolism, which is a separate concept from therapeutic
index, though both apply to digoxin safety in clinical practice.
Q8: A client prescribed oral nitroglycerin for angina prophylaxis asks the nurse why the sublingual form is used for
acute angina attacks instead of the oral form. Which explanation is most accurate regarding bioavailability and route
of administration?
Page 3
NUR210 / NUR 210 Exam 2 (Latest 2026/2027)
Principles of Pharmacology - Galen Tested Questions with Revised Correct Answers
Section 1: Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion) -
Q1-Q10
Q1: A nurse is administering a medication orally to a client. The client asks why the oral dose is higher than the
intravenous dose of the same drug. Which response by the nurse is most accurate regarding the first-pass effect?
A. The oral form is less concentrated because the tablet contains fillers and binders that dilute the active
ingredient
B. The oral drug passes through the liver before reaching systemic circulation, where a significant portion is
metabolized and inactivated, reducing bioavailability
C. The intravenous form bypasses the kidneys, so more drug reaches the systemic circulation compared to the
oral route
D. Oral medications are absorbed more slowly through the stomach lining, requiring a higher dose to
compensate for delayed onset of action
Correct Answer: B
Rationale: The first-pass effect refers to the metabolism of a drug by the liver before it reaches the systemic circulation, which
significantly reduces the bioavailability of orally administered medications. Because a portion of the drug is metabolized and
inactivated during this initial hepatic passage, a higher oral dose is required to achieve the same therapeutic effect as a lower IV
dose that achieves 100% bioavailability. Option A incorrectly describes excipients, which do not affect bioavailability in this
manner. Option C is wrong because the first-pass effect involves the liver, not the kidneys. Option D confuses absorption rate
with bioavailability, which are distinct pharmacokinetic concepts aligned with Galen NUR210 competencies.
Q2: A client with liver cirrhosis is prescribed a medication that is highly protein-bound (98%). The nurse
understands that which factor most significantly affects the pharmacological activity of this drug in this client?
A. The drug will be rapidly excreted by the kidneys due to reduced protein binding sites in the blood
B. Only the unbound (free) fraction of the drug is pharmacologically active, and liver disease may alter
albumin levels, increasing the free drug concentration and risk of toxicity
C. The drug will accumulate in the liver tissue due to cirrhosis, leading to prolonged therapeutic effects
D. Protein-bound drugs are metabolized more quickly in clients with liver disease, reducing the drug half-life
Correct Answer: B
Rationale: Drugs bound to plasma proteins (primarily albumin) are pharmacologically inactive because they cannot cross cell
membranes or interact with receptors. Only the unbound (free) fraction is active. In liver cirrhosis, albumin production is
reduced, leaving fewer binding sites and increasing the free (active) drug concentration, which elevates the risk of toxicity even at
normal doses. This is a critical pharmacokinetic principle taught in Galen NUR210. Option A is incorrect because protein binding
affects distribution, not renal excretion directly. Option C describes distribution to tissues, not the mechanism of altered
pharmacological activity. Option D is false because protein binding does not accelerate metabolism; in fact, less protein binding
means more free drug available for metabolism.
Page 1
,NUR210 Exam 2: Principles of Pharmacology | Galen College of Nursing | 2026/2027 A+ Guarantee
Q3: A nurse is caring for a client receiving warfarin therapy. The healthcare provider prescribes phenytoin for a
new-onset seizure disorder. The nurse anticipates which therapeutic change based on the pharmacokinetic principle
of enzyme induction?
A. Warfarin levels will increase, raising the risk of bleeding, and the INR should be monitored more frequently
B. Phenytoin will increase the metabolism of warfarin by inducing hepatic CYP450 enzymes, decreasing
warfarin levels and potentially reducing its anticoagulant effect
C. Warfarin will inhibit the metabolism of phenytoin, leading to phenytoin toxicity and requiring a dosage
reduction
D. The combination will have an additive effect on the central nervous system, causing excessive sedation and
drowsiness
Correct Answer: B
Rationale: Phenytoin is a potent CYP450 enzyme inducer that increases the hepatic metabolism of warfarin, a drug with a
narrow therapeutic index that is metabolized by the same enzyme system. This enzyme induction accelerates warfarin
breakdown, reducing its plasma concentration and anticoagulant effect, potentially leading to thrombosis if the INR drops below
the therapeutic range of 2-3. The nurse should anticipate more frequent INR monitoring and a potential need to increase the
warfarin dose. Option A describes enzyme inhibition (the opposite effect). Option C reverses the interaction direction. Option D
describes a pharmacodynamic CNS effect that does not apply to these specific medications, reflecting a common NUR210
distractor pattern.
Q4: A client is prescribed a medication with a half-life of 12 hours. The nurse understands that approximately how
long it will take for this drug to reach steady-state therapeutic levels?
A. 12 hours, which equals one complete half-life cycle
B. 24 hours, or approximately two half-lives, which provides sufficient drug accumulation
C. 48 to 60 hours, or approximately 4 to 5 half-lives, at which point drug administration equals drug
elimination
D. 72 hours, or six half-lives, because this ensures maximum drug plasma concentration is achieved
Correct Answer: C
Rationale: Steady state is achieved when the rate of drug administration equals the rate of drug elimination, creating a plateau in
plasma concentration. It takes approximately 4 to 5 half-lives to reach steady state for most medications. For a drug with a
12-hour half-life, this would be 48 to 60 hours. This is a fundamental pharmacokinetic principle emphasized in the Galen
NUR210 curriculum. Option A (1 half-life) reaches only 50% of steady state. Option B (2 half-lives) reaches only 75% of steady
state. Option D (6 half-lives) exceeds the standard 4-5 half-life calculation and is unnecessary for clinical purposes.
Q5: A nurse is reviewing medication orders for a client with chronic kidney disease (CKD) stage 4. Which
pharmacokinetic alteration should the nurse expect for medications that are primarily eliminated by renal excretion?
A. Increased first-pass metabolism leading to reduced drug bioavailability
B. Decreased drug absorption from the gastrointestinal tract due to uremic toxins
C. Reduced renal clearance leading to drug accumulation, prolonged half-life, and increased risk of toxicity
D. Enhanced protein binding increasing the fraction of inactive drug in circulation
Correct Answer: C
Rationale: The kidney is the primary route of drug excretion through glomerular filtration, tubular secretion, and passive
reabsorption. In CKD stage 4, renal function is severely impaired (GFR 15-29 mL/min), leading to significantly reduced drug
Page 2
, NUR210 Exam 2: Principles of Pharmacology | Galen College of Nursing | 2026/2027 A+ Guarantee
clearance for renally eliminated medications. This causes drug accumulation, prolonged half-life, and increased risk of toxicity
unless dosage adjustments are made. This principle is central to safe medication administration in NUR210. Option A describes a
hepatic issue, not renal. Option B refers to absorption, which is not the primary pharmacokinetic concern in CKD. Option D is
incorrect because CKD does not enhance protein binding; it may actually reduce it due to hypoalbuminemia from uremia.
Q6: A postpartum client is breastfeeding and asks the nurse about medication excretion into breast milk. Which
pharmacokinetic factor best explains why some drugs cross into breast milk more readily than others?
A. Drugs with high molecular weight and extensive protein binding are more likely to enter breast milk
B. Drugs that are lipid-soluble, unbound (free), and have low molecular weight more readily cross into breast
milk by passive diffusion
C. Only water-soluble drugs can cross into breast milk because milk is primarily an aqueous environment
D. Drugs that are ionized at physiological pH are preferentially transported into breast milk via active transport
mechanisms
Correct Answer: B
Rationale: Breast milk excretion follows the same principles as distribution across biological membranes. Lipophilic
(lipid-soluble) drugs, unbound (free) drugs, and those with low molecular weight cross more readily into breast milk by passive
diffusion. The pH of breast milk is slightly acidic (pH ~7.0) compared to plasma (pH 7.4), so weakly basic drugs may become
ionized and trapped in milk (ion trapping). Option A is incorrect because high molecular weight and protein binding impede, not
facilitate, passage into breast milk. Option C is wrong because lipophilic, not water-soluble, drugs cross membranes more easily.
Option D is incorrect because ionized drugs do not cross membranes readily via passive diffusion, and only a few drugs use
active transport into milk.
Q7: A nurse is preparing to administer digoxin to a client with heart failure. The nurse understands that digoxin has a
narrow therapeutic index. Which statement best describes the clinical significance of a narrow therapeutic index?
A. The drug has a wide margin of safety, and small dosage variations rarely produce toxic effects
B. The therapeutic index (ratio of toxic dose LD50 to effective dose ED50) is small, meaning the difference
between a therapeutic dose and a toxic dose is minimal, requiring close monitoring
C. The drug requires a loading dose to achieve steady state because it has a very long half-life exceeding 48
hours
D. The drug is primarily metabolized by CYP3A4 and is highly susceptible to drug-drug interactions with
enzyme inhibitors
Correct Answer: B
Rationale: The therapeutic index (TI) is the ratio of the toxic dose (LD50) to the effective dose (ED50). A narrow therapeutic
index means this ratio is small, indicating that the difference between a therapeutic and toxic dose is minimal. Digoxin, along
with warfarin, lithium, theophylline, and phenytoin, are classic examples of narrow therapeutic index drugs that require close
serum level monitoring, precise dosing, and vigilant assessment for signs of toxicity. Option A describes a wide therapeutic
index, which is the opposite. Option C describes a pharmacokinetic property (half-life) related to loading dose rationale, not
therapeutic index. Option D describes a drug interaction risk related to metabolism, which is a separate concept from therapeutic
index, though both apply to digoxin safety in clinical practice.
Q8: A client prescribed oral nitroglycerin for angina prophylaxis asks the nurse why the sublingual form is used for
acute angina attacks instead of the oral form. Which explanation is most accurate regarding bioavailability and route
of administration?
Page 3
